Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.75 |
| ▸ | SCTR | P47872 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30377221 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL29800085 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL30377709 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL30428145 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL29800188 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL29799938 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL31406266 | 1.00 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL30241096 | 0.99 | GLP1R (0.74) | GLP1RSCTR | |
| SCHEMBL30987835 | 0.99 | GLP1R (0.75) | GLP1RSCTR | |
| SCHEMBL30378098 | 0.99 | GLP1R (0.73) | GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111757891-B | Chemo-enzymatic synthesis of Soxhlet Ma Lutai, liraglutide and GLP-1 | 费森尤斯卡比有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | claimed |
| CN-116410297-A | Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof | 内蒙古博睿精创科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | claimed |
| WO-2023000240-A1 | LONG-ACTING GLP-1 POLYPEPTIDE ANALOGUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛博睿精创科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| EP-4602064-B1 | METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE | BACHEM HOLDING AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| EP-4602064-A1 | METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE | Bachem Holding AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4582441-A2 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4291647-B1 | SUBTILISIN VARIANTS AND THEIR USE | FRESENIUS KABI IPSUM S R L (IT) | 2025-06-18 | — | — | EP | disclosed |
| CN-119161410-B | Synthesis method of semaglutin dipeptide fragment | 质肽药业(泰州)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115677845-A | Method for preparing somaglutide by dipeptide feeding at specific site | 前沿生物药业(南京)股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677827-A | Peptide compounds | 深圳市健元医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023000240-A1 | LONG-ACTING GLP-1 POLYPEPTIDE ANALOGUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛博睿精创科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-113429471-B | Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof | 青岛博睿精创科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4073096-A1 | A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE | SANOFI (FR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114867743-A | Methods of forming conjugates of sulfonamides and polypeptides | 赛诺菲 | 2022-08-05 | — | — | CN | disclosed |
| CN-114262358-A | Preparation method of glutamine dipeptide | 苏州天马医药集团天吉生物制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | GCG, OGDH, ABAT | GLP1R 29/4885SCTR 1160/4885 |
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | GLP1R 16/4885SCTR 51/4885 |
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | GIPR, GRPR, SCTR | GLP1R 5/4885SCTR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.